Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases
Conditions: Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis Interventions: Drug: Neratinib maleate in combination with capecitabine Sponsors: Convalife (Shanghai) Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Brain | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Neurology | Research | Xeloda